Candel Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 12, 2026
CADL$9.49+8.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| DECEMBER 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $119,731 | $102,654 |
| Prepaid expenses and other current assets | 1,658 | 1,150 |
| Total current assets | 121,389 | 103,804 |
| Fixed assets, net | 1,642 | 2,191 |
| Lease right of use assets | 1,661 | 542 |
| Restricted cash | 416 | 266 |
| Other assets | 87 | 63 |
| Total assets | $125,195 | $106,866 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $1,129 | $237 |
| Accrued expenses | 7,334 | 5,113 |
| Current portion of term loans | — | 9,895 |
| Current portion of lease liability | 445 | 566 |
| Warrant liabilities | — | 21,718 |
| Other current liabilities | 89 | — |
| Total current liabilities | 8,997 | 37,529 |
| Deferred revenue | 89 | — |
| Term loans, net of current portion | 46,122 | 1,733 |
| Other long-term debt | 1,008 | 870 |
| Lease liability, net of current portion | 1,459 | 407 |
| Warrant liabilities | 15,598 | — |
| Total liabilities | 73,273 | 40,539 |
| Commitments and contingencies (Note 15) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.01 par value; 10,000,000 shares authorized at December 31, 2025 and 2024; no shares issued or outstanding at December 31, 2025 and 2024, respectively. | — | — |
| Common stock, $0.01 par value; 150,000,000 shares authorized at December 31, 2025 and 2024; 55,020,911 and 46,933,088 shares issued at December 31, 2025 and 2024, respectively; and 54,898,303 and 46,810,480 shares outstanding at December 31, 2025 and 2024, respectively. | 550 | 469 |
| Treasury stock (at cost) | (448) | (448) |
| Additional paid-in capital | 282,207 | 258,511 |
| Accumulated deficit | (230,387) | (192,205) |
| Total stockholders’ equity | 51,922 | 66,327 |
| Total liabilities and stockholders’ equity | $125,195 | $106,866 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.